1. Introduction
===============

Endoscopic sinus surgery has emerged as a well-established procedure for the treatment of sinonasal diseases, and often suffers from the difficulty in controlling bleeding.^\[[@R1]--[@R3]\]^ A small amount of bleeding has a negative impact on confined area of visibility during endoscopic sinus surgery, and subsequently the surgery is difficult to perform and the risk of complications may be increased.^\[[@R4]--[@R6]\]^ Controlled hypotension enables us to produce a relatively bloodless surgical field and facilitates surgical dissection, but hypotensive techniques still have certain disadvantages.^\[[@R7],[@R8]\]^

Various drugs have been developed to reduce the side effects, and they mainly include beta-blockers, nitroglycerine, sodium nitroprusside, and magnesium sulfate.^\[[@R9]--[@R11]\]^ For instance, esmolol is one widely used cardio-selective beta-1 receptor blocker with rapid onset and short duration, but has no significant membrane stabilizing activity at therapeutic dosages.^\[[@R12]\]^ Recently, intravenous magnesium sulfate has been found to be a satisfactory agent to achieve controlled hypotension and the clean surgical field for endoscopic sinus surgery via vasodilatation by inhibiting angiotensin converting enzyme activity as well as myocardial depression.^\[[@R13]\]^

However, the benefit of magnesium sulfate versus placebo for the surgical field during endoscopic sinus surgery has not been well established. Recently, several studies on the topic have been published, and the results have been conflicting.^\[[@R12],[@R14],[@R15]\]^ With accumulating evidence, we therefore perform a systematic review and meta-analysis of RCTs to explore the efficacy of magnesium sulfate versus placebo for the surgical field during endoscopic sinus surgery.

2. Materials and methods
========================

Ethical approval and patient consent are not required because this is a systematic review and meta-analysis of previously published studies. The systematic review and meta-analysis are conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).^\[[@R16]\]^

2.1. Search strategy and study selection
----------------------------------------

Two investigators have independently searched the following databases (inception to November 2018): PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. The electronic search strategy is conducted using the following keywords

magnesium sulfate, and endoscopic sinus surgery. We also check the reference lists of the screened full-text studies to identify other potentially eligible trials.

The inclusive selection criteria are as follows: population: patients undergoing endoscopic sinus surgery; intervention: magnesium sulfate; comparison: matched placebo; study design: RCT.

2.2. Data extraction and outcome measures
-----------------------------------------

We have extracted the following information: author, number of patients, age, female, body mass index or weight, American Society of Anesthesiologists (ASA) class (1/2) and detail methods in each group etc. Data have been extracted independently by 2 investigators, and discrepancies are resolved by consensus. We also contact the corresponding author to obtain the data when necessary.

The primary outcome is surgical field scores. Secondary outcomes include intraoperative blood loss, surgery duration, fentanyl, and vecuronium.

2.3. Quality assessment in individual studies
---------------------------------------------

Methodological quality of the included studies is independently evaluated using the modified Jadad scale.^\[[@R17]\]^ There are 3 items for Jadad scale: randomization (0--2 points), blinding (0--2 points), dropouts and withdrawals (0--1 points). The score of Jadad Scale varies from 0 to 5 points. An article with Jadad score≤2 is considered to be of low quality. If the Jadad score≥3, the study is thought to be of high quality.^\[[@R18]\]^

2.4. Statistical analysis
-------------------------

We estimate the mean difference (MD) with 95% confidence interval (CI) for continuous outcomes (surgical field scores, intraoperative blood loss, surgery duration, fentanyl, and vecuronium). A random-effects model is used regardless of heterogeneity. Heterogeneity is reported using the I^2^ statistic, and I^2^ \> 50% indicates significant heterogeneity.^\[[@R19]\]^ Whenever significant heterogeneity is present, we search for potential sources of heterogeneity via omitting 1 study in turn for the meta-analysis or performing subgroup analysis. All statistical analyses are performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

3. Results
==========

3.1. Literature search, study characteristics, and quality assessment
---------------------------------------------------------------------

A detailed flowchart of the search and selection results is shown in Fig. [1](#F1){ref-type="fig"}. Three hundred forty-eight potentially relevant articles are identified initially. Finally, 4 RCTs that meet our inclusion criteria are included in the meta-analysis.^\[[@R12]--[@R15]\]^

![Flow diagram of study searching and selection process.](medi-98-e16115-g001){#F1}

The baseline characteristics of the 4 eligible RCTs in the meta-analysis are summarized in Table [1](#T1){ref-type="table"}. The 4 studies are published between 2006 and 2017, and sample sizes range from 20 to 294 with a total of 404. Magnesium sulfate is administered by 40 mg/kg intravenously as a bolus over 10 minutes before induction of anesthesia, followed by 9 to 30 mg/kg/h through infusion.

###### 

Characteristics of included studies.
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Among the 4 studies included here, 2 studies report surgical field scores,^\[[@R12],[@R14]\]^ 3 studies report intraoperative blood loss,^\[[@R12],[@R14],[@R15]\]^ 3 studies report surgery duration,^\[[@R12],[@R13],[@R15]\]^ 2 studies report fentanyl and vecuronium.^\[[@R14],[@R15]\]^ Jadad scores of the four included studies vary from 3 to 5, and all 4 studies are considered to be high-quality ones according to quality assessment.

3.2. Primary outcome: surgical field scores
-------------------------------------------

This outcome data is analyzed with the random-effects model, and compared to control group for endoscopic sinus surgery, magnesium sulfate results in significantly surgical field scores (MD = −1.76; 95% CI = −2.33 to −1.18; *P* \< .00001) with significant heterogeneity among the studies (I^2^ = 77%, heterogeneity *P* = .04) (Fig. [2](#F2){ref-type="fig"}).

![Forest plot for the meta-analysis of surgical field scores.](medi-98-e16115-g003){#F2}

3.3. Sensitivity analysis
-------------------------

Significant heterogeneity is observed among the included studies for surgical field scores, but there are just 2 RCTs, and it is not available to perform sensitivity analysis via omitting 1 study in turn.

3.4. Secondary outcomes
-----------------------

In comparison with control group for endoscopic sinus surgery, magnesium sulfate is associated with remarkably decreased intraoperative blood loss (MD = −89.09; 95% CI = −163.20 to −14.97; *P* = .02; Fig. [3](#F3){ref-type="fig"}), but has no obvious effect on surgery duration (MD = −7.08; 95% CI = −21.38 to 7.22; *P* = 0.33; Fig. [4](#F4){ref-type="fig"}), fentanyl (MD = −0.64; 95% CI = −1.97 to 0.70; *P* = .35; Fig. [5](#F5){ref-type="fig"}), and vecuronium (MD = −3.64; 95% CI = −10.99 to 3.70; *P* = .33; Fig. [6](#F6){ref-type="fig"}).
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4. Discussion
=============

Magnesium sulfate is a well-established vasodilator by increasing the synthesis of prostacyclin and inhibiting angiotensin converting enzyme activity, and has neuroprotective effect during controlled hypotension.^\[[@R20]--[@R23]\]^ Magnesium is known as a naturally occurring calcium antagonist and a noncompetitive antagonist of the N-methyl-D-aspartate receptor. Cetylcholine release at the motor endplate is hindered because magnesium competes for calcium channels in the presynaptic nerve terminal.^\[[@R24]--[@R26]\]^ Magnesium sulfate has been widely used for controlling blood pressure in preeclampsia, pheochromocytoma and the reduction in blood loss during surgery.^\[[@R15],[@R20],[@R27]\]^

Successful surgery requires a motionless and clear surgical field, and even minimal bleeding interfering with the visualization of the operative area can lead to increased operative time and complications.^\[[@R28]--[@R30]\]^ Previous study reports that magnesium sulfate is capable of reducing arterial pressure, heart rate, blood loss, and duration of sinus surgery.^\[[@R15]\]^ Improved quality of the surgical field is observed after magnesium sulfate application during endoscopic sinus surgery.^\[[@R12]\]^ Our meta-analysis suggests that compared to control group for endoscopic sinus surgery, magnesium sulfate is able to improve surgical field and reduce intraoperative blood loss, but shows no remarkable impact on surgery duration, the dose of fentanyl and vecuronium.

Regarding the sensitivity analysis, there is still significant heterogeneity. However, we cannot perform the sensitivity analysis via omitting one study in turn, because there are just two RCTs for the analysis of surgical field scores. Several reasons may account for this heterogeneity, and they mainly involve different maintenance doses of magnesium sulfate and operation procedures during the surgery. Magnesium sulfate may cause the potential risks such as potentiation of opioids and neuromuscular blockers leading to delayed emergence.^\[[@R31],[@R32]\]^ However, the duration of anesthesia is reduced after the use of magnesium sulfate compared to placebo during endoscopic sinus surgery.^\[[@R12]\]^ In addition, one included RCT reports no episodes of hypotension, arrhythmia or reflex tachycardia during magnesium sulfate infusion, and no patient suffers from rebound hypertension upon discontinuing magnesium sulfate infusion.^\[[@R15]\]^

There are several potential limitations. First, 4 RCTs are included in this meta-analysis, and 3 of them have a relatively small sample size (n \< 100) which may result in some overestimation of the treatment effect. Next, significant heterogeneity is observed and it may result from different procedures of surgery and doses of magnesium use. Finally, the meta-analysis of some important index (e.g., pain scores, mean heart rate, and blood pressure) cannot be conducted based on limited data in current RCTs.

5. Conclusions
==============

Magnesium sulfate can provide obviously improved surgical field for endoscopic sinus surgery.
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